MX2007008021A - Composiciones que incluyen hierro. - Google Patents

Composiciones que incluyen hierro.

Info

Publication number
MX2007008021A
MX2007008021A MX2007008021A MX2007008021A MX2007008021A MX 2007008021 A MX2007008021 A MX 2007008021A MX 2007008021 A MX2007008021 A MX 2007008021A MX 2007008021 A MX2007008021 A MX 2007008021A MX 2007008021 A MX2007008021 A MX 2007008021A
Authority
MX
Mexico
Prior art keywords
iron
dietary
compositions including
including iron
nutritional
Prior art date
Application number
MX2007008021A
Other languages
English (en)
Spanish (es)
Inventor
Jonathan David Bortz
Mitchell I Kirschner
David S Hermelin
Original Assignee
Drugtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugtech Corp filed Critical Drugtech Corp
Publication of MX2007008021A publication Critical patent/MX2007008021A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
MX2007008021A 2004-12-22 2005-10-27 Composiciones que incluyen hierro. MX2007008021A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/020,801 US20060134227A1 (en) 2004-12-22 2004-12-22 Compositions including iron
PCT/US2005/038859 WO2006068697A2 (en) 2004-12-22 2005-10-27 Compositions including iron

Publications (1)

Publication Number Publication Date
MX2007008021A true MX2007008021A (es) 2008-04-11

Family

ID=36596132

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007008021A MX2007008021A (es) 2004-12-22 2005-10-27 Composiciones que incluyen hierro.

Country Status (11)

Country Link
US (5) US20060134227A1 (cg-RX-API-DMAC10.html)
EP (2) EP1827418A4 (cg-RX-API-DMAC10.html)
JP (2) JP2008525442A (cg-RX-API-DMAC10.html)
CN (1) CN101102762A (cg-RX-API-DMAC10.html)
AR (1) AR052837A1 (cg-RX-API-DMAC10.html)
AU (1) AU2005319679A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0519265A2 (cg-RX-API-DMAC10.html)
CA (1) CA2591996A1 (cg-RX-API-DMAC10.html)
MX (1) MX2007008021A (cg-RX-API-DMAC10.html)
PE (1) PE20061122A1 (cg-RX-API-DMAC10.html)
WO (2) WO2006068697A2 (cg-RX-API-DMAC10.html)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
WO2007035760A1 (en) * 2005-09-20 2007-03-29 Board Of Regents, The University Of Texas System Enhanced solubility of preformed calcium citrate by adding citric acid
EP1937287B1 (en) * 2005-10-11 2012-02-29 Bayer Consumer Care AG Mixture of iron and copper salts masking metallic taste
EP1790356A1 (de) * 2005-11-24 2007-05-30 Vifor (International) Ag Präparat, umfassend Eisen(III)-Komplexverbindungen und redoxaktive Substanz(en)
WO2007081744A2 (en) 2006-01-06 2007-07-19 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
MX2009003376A (es) * 2006-09-28 2009-04-08 Bayer Consumer Care Ag Mezcla de sales de hierro y cobre que enmascaran el sabor metalico.
AU2008227465B2 (en) * 2007-03-22 2014-02-06 Magceutics, Inc. Magnesium compositions and uses thereof
US8142803B2 (en) 2007-03-22 2012-03-27 Magceutics, Inc. Magnesium compositions and uses thereof for neurological disorders
US7816404B2 (en) * 2007-07-20 2010-10-19 Rockwell Medical Technologies, Inc. Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
US20090047362A1 (en) * 2007-08-13 2009-02-19 Keith Edward Forrester Method for in-vitro stabilization of heavy metals
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
US7964189B1 (en) 2007-09-25 2011-06-21 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
US9125844B1 (en) 2007-09-25 2015-09-08 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
ITMI20071979A1 (it) * 2007-10-12 2009-04-13 Massimo Baldacci Formulazioni farmaceutiche contenenti ferro bisglicinato chelato
US20090124572A1 (en) * 2007-11-09 2009-05-14 Deanna Jean Nelson Iron-containing nutritional supplement
US8535660B1 (en) 2008-05-27 2013-09-17 Argent Development Group, Llc Nutritional supplements for pregnant women
US8535659B1 (en) 2008-05-27 2013-09-17 Argent Development Group, Llc Nutritional supplements for pregnant women
CN102159205A (zh) 2008-06-25 2011-08-17 Fe3医学有限公司 用于经皮递送治疗有效量的铁的贴片和方法
US20110244057A1 (en) * 2008-09-25 2011-10-06 Ehrenberg Bruce L Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions
US8153573B2 (en) * 2009-01-30 2012-04-10 Ecolab Usa Inc. Development of an aluminum hydroxycarboxylate builder
US8202830B2 (en) 2009-01-30 2012-06-19 Ecolab Usa Inc. Development of an aluminum hydroxydicarboxylate builder
US8821945B2 (en) 2009-04-25 2014-09-02 Fe3 Medical, Inc. Method for transdermal iontophoretic delivery of chelated agents
WO2010136839A1 (en) * 2009-05-29 2010-12-02 Carlo Ghisalberti Use of deferoxamine and related compounds in targeted delivery forms to treat an inflammatory bowel disease
US8178709B2 (en) * 2009-07-21 2012-05-15 Biolink Life Sciences, Inc. Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
KR20120046753A (ko) * 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
US8536106B2 (en) 2010-04-14 2013-09-17 Ecolab Usa Inc. Ferric hydroxycarboxylate as a builder
JP5357102B2 (ja) * 2010-04-27 2013-12-04 日本炉機工業株式会社 石化遺骨灰の製造方法
EP2420243A1 (en) 2010-08-18 2012-02-22 Inovativo Biomedicinas Tehnologiju Instituts, SIA Compositions obtainable from bred beetroot juice to promote iron absorption and blood forming
IT1402142B1 (it) * 2010-09-24 2013-08-28 Just Pharma S R L Formulazione integrativa finalizzata al controllo delle alterazioni multifattoriali ricorrenti nell'anemia da carenza di ferro e per colmare eventuali carenze o aumentati fabbisogni nutrizionali in alcune condizioni fisiopatologiche.
US12612370B2 (en) 2011-03-02 2026-04-28 Thermolife International, Llc Amino acid compositions
EP2497380A1 (en) * 2011-03-10 2012-09-12 DSM IP Assets B.V. Process for iron supplementation of beverages
AR086606A1 (es) 2011-05-31 2014-01-08 Vifor Int Ag Compuestos del complejo de fe(iii) para el tratamiento y profilaxis de los sintomas de la deficiencia de hierro y las anemias por deficiencia de hierro
MX380927B (es) * 2011-09-22 2025-03-12 Amip Promotor de absorcion gi superior amortiguado.
SG11201408521WA (en) * 2012-06-21 2015-01-29 Keryx Biopharmaceuticals Inc Use of ferric citrate in the treatment of chronic kidney disease patients
US20150250839A1 (en) * 2012-09-11 2015-09-10 Dakota Star Capital Llc Nutritional supplement containing iron
CN102961338B (zh) * 2012-12-07 2015-03-18 青岛黄海制药有限责任公司 一种多糖铁缓释微丸制剂及其制备方法
US11331287B2 (en) 2013-06-06 2022-05-17 Balchem Corporation Iron supplement
PL3048903T3 (pl) * 2013-08-28 2017-09-29 Dsm Ip Assets B.V. Suplementacja żelaza koncentratu bulionu
EP3038475B1 (en) * 2013-08-28 2018-06-27 DSM IP Assets B.V. Iron supplementation of a bouillon concentrate
TWI483721B (zh) 2013-09-05 2015-05-11 Profeat Biotechnology Co Ltd The use of a composition containing a ferrous amino acid chelate for the manufacture of anti-cancer medicaments
CA2898771C (en) * 2013-09-05 2017-01-03 Profeat Biotechnology Co., Ltd. Use of composition containing ferrous amino acid chelate in preparation of anti-cancer medicament
US9492421B1 (en) 2013-11-14 2016-11-15 Argent Development Group, Llc Nutritional supplements for treatment of iron deficiency anemia
US9629846B1 (en) 2013-11-14 2017-04-25 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
CN104644557B (zh) * 2013-11-22 2017-10-31 上海宣泰医药科技有限公司 卟啉铁固体分散体及其制备方法
JP2014051535A (ja) * 2013-12-19 2014-03-20 Fujifilm Corp 鉄、カルシウム、又はマグネシウムの吸収を促進する方法
CN104887696B (zh) * 2014-03-04 2018-06-29 天津怀仁制药有限公司 右旋糖酐铁和维生素c的复方制剂
JP6312835B2 (ja) * 2014-08-05 2018-04-18 富士フイルム株式会社 有核赤血球の選別方法
CA2957790A1 (en) 2014-08-13 2016-02-18 Akeso Biomedical, Inc. Antimicrobial compounds and compositions, and uses thereof
GB201416293D0 (en) * 2014-09-15 2014-10-29 Solvotrin Therapeutics Ltd Methods and preparations
JP5757493B1 (ja) * 2014-09-24 2015-07-29 富田製薬株式会社 経口型鉄分補給用固形組成物及びその製造方法
US10913705B2 (en) * 2014-11-07 2021-02-09 Npa—Núcleo De Pesquisas Aplicadas Ltda Iron amino acid compounds, method for preparing iron amino acid compounds, compositions containing iron amino acid compounds, and uses thereof
EP3132798B1 (en) 2014-12-01 2020-03-11 Profeat Biotechnology Co. Ltd. Use of composition containing iron (ii) amino acid chelate in preparing drug for regulating and controlling fat metabolism
CN104474004A (zh) * 2014-12-09 2015-04-01 重庆综艺营养科技有限责任公司 改善贫血的赖氨酸螯合铁生血素
US20170360075A1 (en) * 2014-12-11 2017-12-21 The Penn State Research Foundation Medical food for the treatment of malaria and/or iron deficiency
US10653658B2 (en) 2015-08-11 2020-05-19 Akeso Biomedical, Inc. Biofilm inhibiting compositions enhancing weight gain in livestock
CA2995408C (en) 2015-08-11 2021-01-05 Akeso Biomedical, Inc. Biofilm inhibiting compositions enhancing weight gain in livestock
CN105476953B (zh) * 2015-09-01 2018-10-30 张伟 一种用于补铁的液体制剂及其制备方法
SG10202107245UA (en) * 2015-09-04 2021-08-30 Rockwell Medical Inc Solid soluble ferric pyrophosphate formulations, kits, and methods using the same
JP6919117B2 (ja) * 2015-12-15 2021-08-18 三菱ケミカル株式会社 鉄化合物含有組成物の粒子、鉄化合物の変色抑制方法、並びに鉄化合物及びビタミンｃ含有組成物
EP3199167A1 (de) 2016-01-28 2017-08-02 G.L. Pharma GmbH Arzneimittel zur behandlung von eisenmangelzuständen mit folsäuredefizit
PL3429560T3 (pl) * 2016-03-15 2025-04-28 Solvotrin Therapeutics Ltd. Kompozycje i sposoby zwiększania przyjmowania żelaza u ssaka
WO2017200415A1 (ru) * 2016-05-20 2017-11-23 Общество с ограниченной ответственностью "ВИК-здоровье животных" Инъекционная композиция комплекса железо декстрана с витаминами для профилактики и лечения анемий
EP3466434A4 (en) * 2016-05-26 2020-01-22 Profeat Biotechnology Co. Ltd. USE OF A COMPOSITION WITH FERROUS AMINO ACID CHELATE FOR PRODUCING A MEDICINAL PRODUCT FOR REDUCING LACTIC ACID
CN106265731B (zh) * 2016-09-30 2019-07-19 广西科技大学 硫酸亚铁骨架型缓释滴丸的制备方法
US20190365697A1 (en) * 2017-02-17 2019-12-05 Profeat Biotechnology Co., Ltd. Method for Treating Liver Dysfunction
SG11202001594TA (en) * 2017-09-11 2020-03-30 Pharmacosmos Holding As Iron complex compounds for therapeutic use
CN108635370A (zh) * 2018-07-13 2018-10-12 山东达因海洋生物制药股份有限公司 一种含有右旋糖酐铁的组合物制剂及其制备方法
CN110464011A (zh) * 2018-08-07 2019-11-19 美安康质量检测技术（上海）有限公司 一种补血营养粉及其制备方法
JP2022504310A (ja) * 2018-10-05 2022-01-13 アンパサンド バイオファーマシューティカルズ インコーポレイテッド 局所投与のための鉄製剤および鉄欠乏症の処置の方法
MX2021005095A (es) * 2018-10-31 2021-06-15 My Or Diagnostics Ltd Personalized food products for ensuring adequate iron intake.
CA3087911A1 (en) * 2018-12-20 2020-06-25 Profeat Biotechnology Co., Ltd. Composition comprising ferrous amino acid particles and use thereof in manufacture of medicament for treating or ameliorating pancreas-related disase
CN113260358A (zh) * 2018-12-20 2021-08-13 普惠德生技股份有限公司 含有亚铁胺基酸螯合物粒子的组合物用于制备治疗或减缓神经受损相关疾病的医药品的用途
CN112168843A (zh) * 2019-07-05 2021-01-05 普惠德生技股份有限公司 经烧结的纳米粒子及其抗病毒的用途
EP4291206A4 (en) 2021-02-11 2025-01-08 Thermolife International, LLC A method of administering nitric oxide gas
US12059399B2 (en) * 2021-06-30 2024-08-13 Getwing Biotechnology Medical Co., Ltd Methods for alleviating kidney disease and fibrosis of organ
WO2023272693A1 (zh) * 2021-07-01 2023-01-05 思瑰瑞保健食品有限公司 一种维生素c加硫酸亚铁缓控释片及其制备方法
US20230057399A1 (en) * 2021-08-16 2023-02-23 Thermolife International, Llc Iron supplement compositions and methods of use thereof
CN114028423B (zh) * 2021-12-13 2023-05-23 广东粤港澳大湾区国家纳米科技创新研究院 修饰的纳米氧化铁在制备预防和/或治疗炎性肠病的药物中的应用
CN114288320A (zh) * 2021-12-29 2022-04-08 珠海天翼医药技术开发有限公司 一种猪用口服补铁剂及其制备方法
CN114767710B (zh) * 2022-04-12 2023-07-07 中山大学 甘氨酸亚铁在治疗类风湿关节炎中的应用
CN116636620B (zh) * 2023-05-25 2025-02-14 南昌大学 一种乌鸡蛋清肽组合物及其应用
JP2025044388A (ja) * 2023-09-20 2025-04-02 株式会社東芝 酸性ガス除去方法、酸性ガス吸収剤、および酸性ガス除去装置
WO2026017897A1 (en) 2024-07-18 2026-01-22 Malian Biologicals Gmbh Iron supplementation in affective disorders and/or post-traumatic stress disorder (ptsd) and/or serotonin-dependent diseases
WO2026042887A1 (ja) * 2024-08-23 2026-02-26 株式会社海水化学研究所 鉄分補給剤

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933108A (en) * 1960-02-03 1963-08-08 Haessle Ab Improvements in or relating to pharmaceutical iron preparations
GB1266356A (cg-RX-API-DMAC10.html) * 1968-08-08 1972-03-08
GB1292820A (en) * 1969-08-28 1972-10-11 Aspro Nicholas Ltd Haematinic preparations
GB1338071A (en) * 1970-11-25 1973-11-21 Laso Martinez V Pharmaceutical iron preparations
US3773929A (en) * 1972-11-02 1973-11-20 Diagnostic Data Inc Pharmaceutical compositions comprising orgotein and their use
US4362710A (en) * 1980-07-04 1982-12-07 Nissan Gosei Kogyo Co., Ltd. Feeds for baby pigs, process for preparing the same and method of breeding baby pigs
US4599152A (en) * 1985-05-24 1986-07-08 Albion Laboratories Pure amino acid chelates
US4863898A (en) * 1986-02-06 1989-09-05 Albion International, Inc. Amino acid chelated compositions for delivery to specific biological tissue sites
US4752479A (en) * 1986-05-27 1988-06-21 Ciba-Geigy Corporaton Multi vitamin and mineral dietary supplement with controlled release bioavailable iron
US4830716B1 (en) * 1986-07-03 1999-12-07 Albion Int Preparation of pharmaceutical grade amino acid chelates
US4822816A (en) * 1987-04-10 1989-04-18 Oxycal Laboratories, Inc. Compositions and methods for administering vitamin C
US5070085A (en) * 1987-04-10 1991-12-03 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
FR2642420B1 (fr) * 1989-01-27 1991-09-06 Valpan Sa Labo Pharma Nouvelle forme galenique a liberation programmee contenant une association de sels ferreux, d'acide succinique et d'acide ascorbique
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
HU207799B (en) * 1991-07-24 1993-06-28 Beres Export Import Rt Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis
US5662922A (en) * 1992-01-20 1997-09-02 Christensen; Borge Holm Iron-containing composition for the prevention of anaemia and a method for producing the composition
US5516925A (en) * 1994-08-23 1996-05-14 Albion International, Inc. Amino acid chelates having improved palatability
JP2590449B2 (ja) * 1995-04-21 1997-03-12 農林水産省畜産試験場長 新生子牛の造血機能の改善及び貧血の予防方法
CA2235618C (en) * 1995-10-27 2002-09-03 William John Henry Jr. Color stable iron, zinc and vitamin fortified dry drink mixes
US5770226A (en) * 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
CA2230801A1 (en) * 1998-02-27 1999-08-27 Stanley H. Zlotkin Composition comprising micro-encapsulated iron
US6521247B1 (en) * 1999-08-13 2003-02-18 Warner Chilcott Laboratories Ireland Limited Dual iron containing nutritional supplement
US6495177B1 (en) * 1999-08-13 2002-12-17 Warner Chilcott Laboratories Ireland Limited Orally dissolvable nutritional supplement
MXPA02007248A (es) * 2000-01-28 2002-12-09 Procter & Gamble Compuestos de arginina con sabor aceptable y usos de los mismos para la salud cardiovascular.
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
US6716814B2 (en) * 2001-08-16 2004-04-06 Albion International, Inc. Enhancing solubility of iron amino acid chelates and iron proteinates
US6906038B2 (en) * 2001-08-29 2005-06-14 Abbott Laboratories Methods for alleviating mucositis
US20030190355A1 (en) * 2002-04-05 2003-10-09 Hermelin Marc S. Modified release minerals
US7994217B2 (en) * 2002-05-02 2011-08-09 Xanodyne Pharmaceuticals, Inc. Prenatal multivitamin/multimineral supplement
AU2003246644A1 (en) * 2002-07-08 2004-01-23 Genova, Ltd. Secreted peptides
US20030045473A1 (en) * 2002-07-19 2003-03-06 Sarama Robert Joseph Compositions, kits, and methods for cardiovascular health
US8007846B2 (en) * 2006-01-18 2011-08-30 Albion International, Inc. Mixed amino acid/mineral compounds having improved solubility

Also Published As

Publication number Publication date
US20090028962A1 (en) 2009-01-29
PE20061122A1 (es) 2006-10-16
WO2006068729A3 (en) 2007-01-18
CN101102762A (zh) 2008-01-09
US20060134227A1 (en) 2006-06-22
BRPI0519265A2 (pt) 2009-01-06
WO2006068697A3 (en) 2006-12-21
EP1827418A2 (en) 2007-09-05
US20130189374A1 (en) 2013-07-25
CA2591996A1 (en) 2006-06-29
EP1827419A4 (en) 2011-08-17
US20110015150A1 (en) 2011-01-20
AU2005319679A1 (en) 2006-06-29
EP1827419A2 (en) 2007-09-05
WO2006068697A2 (en) 2006-06-29
US20160022631A1 (en) 2016-01-28
AR052837A1 (es) 2007-04-04
EP1827418A4 (en) 2011-08-24
JP2008525442A (ja) 2008-07-17
WO2006068729A2 (en) 2006-06-29
JP2008525445A (ja) 2008-07-17

Similar Documents

Publication Publication Date Title
WO2006068697A3 (en) Compositions including iron
MX2007007781A (es) Composiciones cardiovasculares.
EP3318262A3 (en) Composition for preventing or treating bone disease, obesity and lipid-related metabolic disease
PT2170090E (pt) Óleos enriquecidos com hidroxitirosol e suas utilizações
IL154318A0 (en) Pharmaceutical compositions for the treatment of movement disorders
MX2009012255A (es) Probioticos en ambiente pre y/o postquirurgico.
IL186788A0 (en) Nutritional supplement for hiv patients
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
MY147247A (en) Organic compounds and their uses
MY146112A (en) Long-term feed - cancer patient
PH12012502279A1 (en) Tube feed formulations and methods for using same
AU304435S (en) Pet food supplement
EP4424368A3 (en) Compositions comprising an urolithin compound
WO2010019212A3 (en) Methods for enhancing energy metabolism
EP2241196A3 (en) Nutritional supplement comprising oligosaccharides and cysteine for treating hiv
PT1876906E (pt) Suplemento alimentar ou alimento funcional contendo uma combinação de óleos
PH12013500761A1 (en) Cysteine and food intake
MX347263B (es) Metodos para incrementar la produccion o actividad de catalasa.
RU2009134848A (ru) Транквилизатор и функциональный продукт питания
MX2007011264A (es) Composiciones nutricionales para modular la biodisponibilidad de vitamina c.
TW200728295A (en) Benzochromene derivatives
WO2008008513A3 (en) Combination treatments
PH12020500606A1 (en) Use of functionalized calcium carbonate as active ingredient
ATE424120T1 (de) Betainhaltige nahrung gegen muskelschwund
WO2006011136A3 (en) Novel naphthoquinone derivatives and uses thereof